DUBLIN--(BUSINESS WIRE)--The "Cell Therapy Consumables Market by Type of Consumable, Type of Cell Therapy, Scale of Operation, Type of End-User and Key Geographical Regions: Industry Trends and Global Forecasts, 2021 - 2031" report has been added to ResearchAndMarkets.com's offering.
This report features an extensive study on the consumable providers within the cell therapy industry. The study also includes an elaborate discussion on the future potential of this evolving market.
According to the US Food and Drug Administration (FDA), there has been an evident increase in the number of cell and gene therapy products being evaluated in early phases of development. This can further be validated by the observed upsurge in the number of investigational new drug (IND) applications. In fact, more than 800 IND applications have been filed for ongoing clinical studies, indicating remarkable scientific progress and therapeutic promise of these breakthrough drug candidates. However, manufacturing of cell therapies is a complex and capital-intensive process fraught with a wide range of challenges. Some of the key concerns of contemporary innovators include raw material supply constraints, current facility limitations, high cost of ancillary materials (buffers, growth factors and media) used in upstream processes, regulatory and compliance-related issues, and inconsistencies related to quality attributes of the final product. Further, the onset of recent COVID-19 pandemic has created additional challenges for therapy developers, in terms of procuring the required raw materials, by disrupting well-established supply chains.
Recent reports indicate that the global demand for human serum albumin (a key component of cell culture media for use in a multitude of therapeutic and emerging biotech areas) has increased at an annual rate of 10%-15%. On the contrary, the use of animal components is highly disregarded by the US FDA, European Medicines Agency (EMA), and other regulatory bodies on the grounds that they pose an undesirable risk of transmitting infectious agents, such as prions (mad cow disease) and virus (HIV), as well as enable high batch-to-batch variation. Consequently, serum-free and xeno-free media have proven to be a promising alternative to serum derived components. In order to produce quality cellular therapies, several drug developers prefer to rely on third-party service providers for the supply of raw materials, such as cell culture medium, cell isolation kits and cell separation reagents.
Presently, over 60 service providers are actively engaged in providing consumable/raw material products for the production of cell therapies. The current consolidated market landscape is primarily dominated by the presence of large players, capturing a substantial proportion of the market share. In the recent past, many of the aforementioned service providers have also forged strategic alliances and/or acquired other players, in order to further enhance their respective service offerings. Given that the demand for cell therapies is indubitably rising, the corresponding opportunity for cell therapy consumable service providers is expected to witness steady growth, over the next decade.
Key Questions Answered
- Who are the key players, across the world, engaged in offering consumables for cell therapies?
- Which regions have emerged as key hubs in terms of cell therapy consumable related capabilities?
- Which are the most popular media components used for cell therapy consumables?
- What kind of partnership models are most commonly adopted by stakeholders engaged in this industry?
- How is the recent COVID-19 pandemic likely to impact the consumables market for cell therapies?
- What are the key challenges associated with cell therapy consumables?
- What is the current, global demand (kits, media and reagents) for cell therapy consumables in the manufacturing process?
- How is the current and future market opportunity likely to be distributed across key market segments?
- What are the anticipated future trends related to consumables market for cell therapies?
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET LANDSCAPE
5. COMPANY COMPETITIVENESS ANALYSIS
6. BRAND POSITIONING OF KEY INDUSTRY PLAYERS
7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Miltenyi Biotec
7.2.1. Company Overview
7.2.2. Product Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. STEMCELL Technologies
7.4. Bio-Techne
7.5. Irvine Scientific
7.6. Thermo Fisher Scientific
7.7. Sartorius
7.8. BD Biosciences
7.9. Lonza
7.10. CellGenix
7.11. Corning
8. RECENT DEVELOPMENTS AND INITIATIVES
9. LIKELY PARTNER ANALYSIS FOR CELL THERAPY CONSUMABLE PROVIDERS
10. DEMAND ANALYSIS
11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12. UPCOMING TRENDS AND FUTURE GROWTH OPPORTUNITIES
13. IMPACT OF COVID-19 ON CELL THERAPY CONSUMABLES MARKET
14. CONCLUDING REMARKS
15. INTERVIEW TRANSCRIPTS
16. APPENDIX I: TABULATED DATA
17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/17t5mu
